Boehringer Ingelheim’s R&D in Immunology

Boehringer Ingelheim has a vision to transform the treatment of immune diseases and the lives of patients, supporting the families and physicians that care for them. 

In addition to BI 655066, several compounds are in early clinical stages of development, for people living with other immune diseases. 

Our frontrunner projects comprise biologicals, i.e. monoclonal antibodies targeting clinically relevant cellular and molecular targets in crucial pathways for immune responses of the body.

With the current advanced clinical trials programme, the focus is not only on psoriasis, but also on a wide range of immune diseases with unmet need such as

• Psoriatic arthritis,
• Crohn’s disease,
• Inflammatory Bowel Diseases
• Lupus nephritis
• as well as severe Asthma.